KRSA completes merger closing with Cyclerion; $380M private placement
Korsana Biosciences (KRSA) completed the closing of its merger with Cyclerion Therapeutics and the previously announced private placement of $380 million.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.